Part of The Mesothelioma Center. Contact Us
Mesothelioma-Line.com.
Journal Articles on Mesothelioma: Cancer Information for Patients and Families

Archive for the 'Bevacizumab (Avastatin)' Category

Bevacizumab (Avastatin) news feed.

October 2nd, 2008. Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

Pemetrexed, a multitargeted antifolate agent, has shown clear activity in several tumors, including mesothelioma and NSCLC. In a phase III trial, second-line treatment with pemetrexed demonstrated overall survival comparable to docetaxel, with a more manageable toxicity profile.
Posted in Bevacizumab (Avastatin), Carboplatin, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Docetaxel (Taxotere), Full Archive, Gemcitabine (Gemzar), Pemetrexed (Alimta), Treatment, Type of Assessment:, paclitaxel | No Comments »

June 11th, 2008. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

Conclusions: The combination of erlotinib and bevacizumab was tolerated reasonably well, but there was no evidence of radiographic response. This study demonstrates the feasibility of conducting trials in mesothelioma patients who have failed first-line therapy. More therapeutic studies with effective agents are needed for these patients.
Posted in Bevacizumab (Avastatin), Chemotherapy, Erlotinib (Tarceva®), Full Archive, Treatment, Type of Assessment: | No Comments »

May 27th, 2008. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599

Conclusion: Based on the data reviewed, > 70% of patients who might otherwise have been eligible for standard advanced NSCLC trials were not candidates for ECOG 4599. Outcome with respect to this study must be interpreted in the context of eligibility restrictions.
Posted in Bevacizumab (Avastatin), Carboplatin, Chemotherapy, Full Archive, Treatment, Type of Assessment:, paclitaxel | No Comments »

February 22nd, 2008. Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007 – an update

Antiangiogenic agents such as bevacizumab (Avastatin) may be of interest but need to be tested in phase 3 trials. The Mesothelioma Avastatin Pemetrexed Study (MAPS) is ongoing, coordinated by the French Thoracic Cancer Intergroup (IFCT).
Posted in Angiogenesis, Bevacizumab (Avastatin), CT or CAT scan, Causation, Chemotherapy, Diagnosis & Differentiation, Epidemiological, Extrapleural Pneumonectomy (EPP), Full Archive, General, Immunohistochemistry or IHC, PET Scan, Pemetrexed (Alimta), Pleural, Surgery, Treatment, Type of Assessment:, Type of Mesothelioma:, thoracoscopy | No Comments »

October 3rd, 2007. The Therapeutic Efficacy of Anti–Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice

Conclusions: These results suggest that the combined use of bevacizumab and pemetrexed may therefore be promising for controlling the progression of MPM highly expressing VEGF.
Posted in Bevacizumab (Avastatin), Chemotherapy, Determining Efficacy, EGFR, Full Archive, New & Novel, Pemetrexed (Alimta), Pleural, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
Goldberg, Persky & White, P.C. Mesothelioma Lawyers